Uncovering the Immune Tumor Microenvironment in Non-small Cell Lung Cancer to Understand Response Rates to Checkpoint Blockade and Radiation

Overview

Journal Transl Lung Cancer Res

Date 2017 May 23

PMID 28529897

Citations 22

Authors

Jonathan E Schoenhals

Steven N Seyedin

Clark Anderson

Eric D Brooks

Yun R Li

Ahmed I Younes

Sharareh Niknam

Ailin Li

Hampartsoum B Barsoumian

Maria Angelica Cortez

James W Welsh

Affiliations

Soon will be listed here.

Abstract

The study of immunology has led to breakthroughs in treating non-small cell lung cancer (NSCLC). The recent approval of an anti-PD1 checkpoint drug for NSCLC has generated much interest in novel combination therapies that might provide further benefit for patients. However, a better understanding of which combinations may (or may not) work in NSCLC requires understanding the lung immune microenvironment under homeostatic conditions and the changes in that microenvironment in the setting of cancer progression and with radiotherapy. This review provides background information on immune cells found in the lung and the prognostic significance of these cell types in lung cancer. It also addresses current clinical directions for the combination of checkpoint inhibitors with radiation for NSCLC.

Citing Articles

Navigating the Complexity of Resistance in Lung Cancer Therapy: Mechanisms, Organoid Models, and Strategies for Overcoming Treatment Failure.

Kang D, Lee J, Im S, Chung C Cancers (Basel). 2024; 16(23).

PMID: 39682183 PMC: 11640395. DOI: 10.3390/cancers16233996.

Immune killer cells treatment for previously treated stage IV NSCLC patients.

Tseng Y, Ho C, Chian C, Chiang C, Chao H, Tsai C Sci Rep. 2024; 14(1):19374.

PMID: 39169058 PMC: 11339402. DOI: 10.1038/s41598-024-69587-x.

Implications of ZNF334 gene in lymph node metastasis of lung SCC: potential bypassing of cellular senescence.

Khashei Varnamkhasti K, Moghanibashi M, Naeimi S J Transl Med. 2024; 22(1):372.

PMID: 38637790 PMC: 11025273. DOI: 10.1186/s12967-024-05115-9.

A Novel Gene Signature based on Immune Cell Infiltration Landscape Predicts Prognosis in Lung Adenocarcinoma Patients.

Ma C Curr Med Chem. 2024; 31(38):6319-6335.

PMID: 38529604 DOI: 10.2174/0109298673293174240320053546.

Potential association of HSPD1 with dysregulations in ribosome biogenesis and immune cell infiltration in lung adenocarcinoma: An integrated bioinformatic approach.

Aluksanasuwan S, Somsuan K, Ngoenkam J, Chutipongtanate S, Pongcharoen S Cancer Biomark. 2023; 39(3):155-170.

PMID: 37694354 PMC: 11091585. DOI: 10.3233/CBM-220442.

References

Dieu-Nosjean M, Antoine M, Danel C, Heudes D, Wislez M, Poulot V . Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008; 26(27):4410-7. DOI: 10.1200/JCO.2007.15.0284. View

Schatton T, Scolyer R, Thompson J, Mihm Jr M . Tumor-infiltrating lymphocytes and their significance in melanoma prognosis. Methods Mol Biol. 2013; 1102:287-324. DOI: 10.1007/978-1-62703-727-3_16. View

Kadota K, Nitadori J, Ujiie H, Buitrago D, Woo K, Sima C . Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma: Tumor-Infiltrating CD10+ Neutrophil/CD20+ Lymphocyte Ratio as an Independent Prognostic Factor. J Thorac Oncol. 2015; 10(9):1301-1310. PMC: 4545576. DOI: 10.1097/JTO.0000000000000617. View

Gentles A, Newman A, Liu C, Bratman S, Feng W, Kim D . The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015; 21(8):938-945. PMC: 4852857. DOI: 10.1038/nm.3909. View

Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

Selby M, Engelhardt J, Quigley M, Henning K, Chen T, Srinivasan M . Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2014; 1(1):32-42. DOI: 10.1158/2326-6066.CIR-13-0013. View

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

Kowalski M, Dubouix-Bourandy A, Bajmoczi M, Golan D, Zaidi T, Coutinho-Sledge Y . Host resistance to lung infection mediated by major vault protein in epithelial cells. Science. 2007; 317(5834):130-2. PMC: 3685177. DOI: 10.1126/science.1142311. View

Zhang B, Yao G, Zhang Y, Gao J, Yang B, Rao Z . M2-polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma. Clinics (Sao Paulo). 2011; 66(11):1879-86. PMC: 3203959. DOI: 10.1590/s1807-59322011001100006. View

10.

Geng Y, Shao Y, He W, Hu W, Xu Y, Chen J . Prognostic Role of Tumor-Infiltrating Lymphocytes in Lung Cancer: a Meta-Analysis. Cell Physiol Biochem. 2015; 37(4):1560-71. DOI: 10.1159/000438523. View

11.

Welsh T, Green R, Richardson D, Waller D, OByrne K, Bradding P . Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol. 2005; 23(35):8959-67. DOI: 10.1200/JCO.2005.01.4910. View

12.

Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M . Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2013; 141(2):125-39. DOI: 10.1016/j.pharmthera.2013.09.004. View

13.

Siziopikou K, Harris J, Casey L, Nawas Y, Braun D . Impaired tumoricidal function of alveolar macrophages from patients with non-small cell lung cancer. Cancer. 1991; 68(5):1035-44. DOI: 10.1002/1097-0142(19910901)68:5<1035::aid-cncr2820680522>3.0.co;2-d. View

14.

Liu C, Wang Y, Wang C, Feng P, Ko H, Liu Y . Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 2009; 136(1):35-45. DOI: 10.1007/s00432-009-0634-0. View

15.

Al-Shibli K, Al-Saad S, Donnem T, Persson M, Bremnes R, Busund L . The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology. 2009; 55(3):301-12. DOI: 10.1111/j.1365-2559.2009.03379.x. View

16.

Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T . Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer. 2008; 113(6):1387-95. DOI: 10.1002/cncr.23712. View

17.

Min L, Mohammad Isa S, Shuai W, Piang C, Nih F, Kotaka M . Cutting edge: granulocyte-macrophage colony-stimulating factor is the major CD8+ T cell-derived licensing factor for dendritic cell activation. J Immunol. 2010; 184(9):4625-9. DOI: 10.4049/jimmunol.0903873. View

18.

Martin T, Frevert C . Innate immunity in the lungs. Proc Am Thorac Soc. 2005; 2(5):403-11. PMC: 2713330. DOI: 10.1513/pats.200508-090JS. View

19.

Perkins D, Wang Z, Donovan C, He H, Mark D, Guan G . Regulation of CTLA-4 expression during T cell activation. J Immunol. 1996; 156(11):4154-9. View

20.

Goc J, Germain C, Vo-Bourgais T, Lupo A, Klein C, Knockaert S . Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 2013; 74(3):705-15. DOI: 10.1158/0008-5472.CAN-13-1342. View